Fifth Third Wealth Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT

Key Points

• Fifth Third Wealth Advisors cut its Abbott Laboratories stake by 32.6% in the second quarter, selling 14,830 shares and retaining 30,646 shares valued at approximately $2.78 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott reported stronger-than-expected quarterly results, with EPS of $1.31 and revenue of $12.59 billion; revenue increased 13% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $118.67.
• Growth opportunities include Abbott’s collaboration with Alphabet on its Lingo glucose monitor and continued momentum in established pharmaceuticals, although the stock’s elevated valuation—a forward P/E above 36—could limit further gains without sustained earnings execution.

Fifth Third Wealth Advisors LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 32.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,646 shares of the healthcare product maker's stock after selling 14,830 shares during the quarter. Fifth Third Wealth Advisors LLC's holdings in Abbott Laboratories were worth $2,781,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $111.27 on Monday. The firm has a market capitalization of $192.53 billion, a PE ratio of 36.01, a P/E/G ratio of 2.15 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $97.67 and a two-hundred day moving average price of $99.77. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's payout ratio is presently 81.55%.

Analysts Set New Price Targets

A number of research analysts have weighed in on ABT shares. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target for the company. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research note on Wednesday, May 27th. Finally, TD Cowen reissued a "buy" rating and set a $115.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average price target of $118.67.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source